U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT07445022) titled 'RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma' on Feb. 25.
Brief Summary: This study is a prospective, open-label, multicenter, real-world clinical study to evaluate the efficacy and safety of tunlametinib in patients with NRAS-mutant advanced melanoma who have failed prior anti-PD-1/PD-L1 therapy.
Study Start Date: Jan. 28
Study Type: INTERVENTIONAL
Condition:
Melanoma Advanced
Intervention:
DRUG: tunlametinib
Tunlametinib will be administered at a dose of 12 mg orally, twice daily, continuously, in 4-week treatment cycles. Study treatment will continue until the occurrence of intolerable toxicity, PD, withdrawal of c...